NAS:ETTX (USA)
Entasis Therapeutics Holdings Inc $ 2.64 0.11 (4.35%)
Volume:
853,911
Avg Vol (1m):
742,571
Market Cap $:
93.66 Mil
Enterprise Value $:
33.93 Mil
P/E (TTM):
0.00
P/B:
1.27
Financial Strength | 5/10 |
Current | Vs Industry | Vs History | |
---|---|---|---|
Cash-To-Debt | 41.88 | ||
Debt-to-Equity | 0.02 | ||
Debt-to-EBITDA | -0.03 | ||
Piotroski F-Score | 3 | ||
Beneish M-Score | -4.87 | ||
WACC vs ROIC |
Profitability Rank | 1/10 |
Current | Vs Industry | Vs History | |
---|---|---|---|
Operating Margin % | -771.7 | ||
Net Margin % | -769.1 | ||
ROE % | -113.93 | ||
ROA % | -97.74 | ||
ROC (Joel Greenblatt) % | -1990.97 | ||
3-Year EBITDA Growth Rate | 12.8 | ||
3-Year EPS without NRI Growth Rate | 13.5 |
ETTX
Valuation Rank |
Current | Vs Industry | Vs History | |
---|---|---|---|
PB Ratio | 1.27 | ||
PS Ratio | 4.96 | ||
EV-to-EBIT | -0.63 | ||
EV-to-EBITDA | -0.63 | ||
Current Ratio | 9.97 | ||
Quick Ratio | 9.97 |
Dividend & Buy Back |
Current | Vs Industry | Vs History | |
---|---|---|---|
3-Year Average Share Buyback Ratio | -52.9 |
Valuation & Return |
Current | Vs Industry | Vs History | |
---|---|---|---|
Price-to-Tangible-Book | 1.27 | ||
Earnings Yield (Greenblatt) % | -158.73 |